LaunchTrends: Xofigo (Prostate Cancer) (US) (Wave 3) | 2014
LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer HealthCare’s radium-223).
LaunchTrends®: Xofigo measures the impact of this new agent on the metastatic castrate-resistant prostate cancer (mCRPC) market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. These reports evaluate physicians’ current awareness and perception of Xofigo relative to other currently available therapies for mCRPC, current and anticipated use of Xofigo, and promotional activity of Xofigo.
Related Market Assessment Reports
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
